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ABSTRACT
Protein arginine methyltransferases (PRMT) have
been implicated in the regulation of transcription.
They are recruited to promoters via interaction with
transcription factors and exert their coactivator
function by methylating arginine residues in his-
tones and other chromatin proteins. Here, we
employ an unbiased approach to identify novel
target genes, which are under the control of two
members of the enzyme family, PRMT1 and CARM1/
PRMT4 (coactivator associated arginine methyl-
transferase 1). By using cDNA microarray analysis,
we find that the siRNA-mediated single knockdown
of neither CARM1 nor PRMT1 causes significant
changes in gene expression. In contrast, double
knockdown of both enzymes results in the deregu-
lated expression of a large group of genes, among
them the CITED2 gene. Cytokine-stimulated expres-
sion analysis indicates that transcriptional activ-
ation of CITED2 depends on STAT5 and the
coactivation of both PRMTs. ChIP analysis identifies
the CITED2 gene as a direct target gene of STAT5,
CARM1 and PRMT1. In reporter gene assays, we
show that STAT5-mediated transcription is coop-
eratively enhanced by CARM1 and PRMT1.
Interaction assays reveal a cytokine-induced asso-
ciation of STAT5 and the two PRMTs. Our data
demonstrate a widespread cooperation of CARM1
and PRMT1 in gene activation as well as repression
and that STAT5-dependent transcription of the
CITED2 gene is a novel pathway coactivated by
the two methyltransferases.
INTRODUCTION
Protein arginine methylationis a covalent posttranslational
modiﬁcation carried out by a family of enzymes, the
PRMTs (protein arginine methyltransferases), which are
evolutionary conserved in eukaryotes from fungi to plants
and mammals (1). In humans, the PRMT family consists of
nine members (2,3). PRMTs use S-adenosylmethionine
(SAM) as methyl donor and add one or two methyl groups
onto the guanidino nitrogens of the arginine residue. The
majority of PRMTs catalyse the formation of asymmetric
dimethyl-arginine by transferring both methyl groups to
the same nitrogen atom, whereas PRMT5 and PRMT7
generate symmetric dimethylation (2). Unmodiﬁed and
monomethyl arginines can be either converted by the pepti-
dylarginine deiminases PAD4 to citrulline or demethylated
by the Jumonji domain-containing protein JMJD6 (4–6).
As reﬂected by the diversity of their substrates, PRMTs
are implicated in the regulation of a plethora of cellular
processes, among which regulation of chromatin-related
processes has been well studied (2). Chromatin-related
functions of PRMTs comprise regulation of DNA-repair,
imprinting and gene expression. PRMT1 and PRMT6
inﬂuence nucleotide excision repair by modiﬁcation of
DNA polymerase b (7,8). PRMT7 plays a role in
male-speciﬁc imprinting (9). Trancriptional regulation
is conducted by several family members: PRMT1,
CARM1/PRMT4 (coactivator associate arginine methyl-
transferase 1), PRMT5, and PRMT6 (10–14). To fulﬁl
their function in gene expression the enzymes are
recruited via interaction with transcription factors to
target promoters, where they aﬀect gene activity in
a methyltransferase-dependent manner and modify his-
tones and other chromatin-associated proteins. Promoter
binding of PRMT5 associates with transcriptional
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been identiﬁed as individual coactivators for a number of
transcription factors. For example, CARM1 enhances
NFkB- (17), MEF2- (18) and bCatenin/TCF-mediated
gene expression (19) and PRMT1 is a coactivator for YY1
(20). Recent ﬁndings suggest that PRMT1 and CARM1
not only synergize in their transcriptional function with
one another but also with histone acetyltransferases, e.g.
in gene regulation by nuclear hormone receptors (NR)
(21–23) and p53 (24).
Whereas the molecular impact of arginine methylation of
histones is still obscure, arginine methylation of other non-
histone chromatin proteins has been shown to control
assembly or disassembly of coactivator and corepressor
complexes. For example, methylation of the transcriptional
coregulators CBP/p300 (25), SRC-3 (26,27), PGC-1 (28),
NIP45 (29) and RIP140 (30) by CARM1, PRMT1, respec-
tively modulates their interactions with other proteins. This
is in agreement with the observation that methylation
increases the hydrophobicity of the arginine and hence
alters intra- as well as intermolecular interactions (1).
To study individual and cooperative functions of
CARM1 and PRMT1 in gene expression in greater
detail and to identify novel signalling pathways, which
are transcriptionally regulated by these two enzymes, we
carried out a screen for novel target genes. We established
short interfering RNA (siRNA)-mediated single and
double knockdowns for CARM1 and/or PRMT1 in
HeLa cells and performed a cDNA microarray expression
proﬁling. Whereas comparison of wild-type and single
knockdown cells showed no diﬀerential expression pat-
tern, a group of 46 genes were signiﬁcantly deregulated in
the CARM1 and PRMT1 double knockdown cells
suggesting a widespread cooperation of the two enzymes
in the control of gene expression. For the CITED2 gene,
which was downregulated upon codepletion of both
PRMTs in the microarray analysis, we found that its
expression is activated by interleukin-4 (IL-4) stimulation
in a STAT5-dependent manner. By means of ChIP
(chromatin immuoprecipitation) analysis, reporter gene
assays and interaction studies we show that CARM1 and
PRMT1 are coactivators of the STAT5-mediated tran-
scription of the CITED2 gene upon IL-4-stimulation.
MATERIALS AND METHODS
Cell linesand antibodies
Hela cells were maintained in Dulbecco’s modiﬁed Eagle’s
medium (DMEM) supplemented with 10% fetal calf
serum (FCS, Gibco/BRL) at 378C and 5% CO2. Cells
were treated with 20ng/ml interleukin-4 (IL-4, recombi-
nant, Stratmann, Hamburg). The following antibodies
were employed: anti-PRMT1 from Upstate (07-404), anti-
PRMT1 generated in rabbits against recombinant human
PRMT1 protein (aa 1–343), anti-CARM1 from Upstate
(07-080), anti-CARM1 generated in rabbits against
recombinant murine PRMT4 protein (aa 433–608), anti-
H4 R3me2 from Upstate (07-213), anti-H3 R17me2
from Abcam (ab8284), anti-STAT5a/b from Santa Cruz,
CA, USA (sc-835), anti-phospho Tyr694/699 STAT5 from
Cell Signaling (9351), anti-STAT6 from Santa Cruz
(sc-981), anti-phospho Tyr641 STAT6 from Cell Signaling
(9361) and anti-b tubulin (MAB3408) from Chemicon,
Billerica, MA, USA.
Plasmids
The pSG5-HA mCARM1 and pGEX-4T1 mCARM1 has
been previously published (31). The pGEX-4T1 hPRMT1
was published by ref. (32) and pcDNA3.1 hPRMT1 by
ref. (33). The pGL3 (STAT5-RE)6-luc was a gift from Iris
Behrmann. The pECE-STAT5b was described by ref. (34).
siRNA transfections
The siRNA oligonucleotide duplexes were purchased from
Dharmacon for targeting the human PRMT1, CARM1,
STAT5 and STAT6 transcripts, respectively in HeLa
cells. The siRNA against STAT5 does not distinguish
between STAT5a and b. The siRNA sequences are (sense
strand indicated): siPRMT1_1 50-CGUGUAUGGCUU
CGACAUG-30, siPRMT1_2 50-UCAAAGAUGUGGCC
AUUAA-30, siCARM1_1 50-CAUGAUGCAGGACUAC
GUG-30, siCARM1_2 50-GGACAUGUCUGCUUAUU
GC-30,s i S T A T 55 0-GCAGCAGACCAUCAUCCUG-30,
siSTAT6 50-GAUGUGUGAAACUCUGAAC-30 and
siNON-targeting 50-UUGAUGUGUUUAGUCGCUA-30.
siRNA duplexes (80nM ﬁnal concentration) were trans-
fected with Oligofectamine (Invitrogen, Karlsruhe,
Germany) for 2 days. Afterwards, cells were treated
without or with stimulus (IL-4) and harvested for RNA
or protein preparation.
cDNA microarray hybridization
Total RNA was prepared from siRNA-treated HeLa cells
using the peqGOLD total RNA kit (PeqLab, Erlangen,
Germany). One microgram of RNA was ampliﬁed using
the MessageAmpTM II aRNA Ampliﬁcation kit (Ambion,
Austin, TX, USA). Ampliﬁed RNA measuring 0.8–2mg
were employed to synthesize Cy3 and Cy5-labelled cDNA
using random nonamer primers. We used a cDNA array,
which comprised the Human Sequence-veriﬁed cDNA
Unigene Set gf200, gf201u and gf202 gene sets (ResGen/
Invitrogen/Cat.No.97001.V) covering 11552 sequence-
veriﬁed cDNAs. Each experiment was performed as
sandwich hybridization, i.e., instead of a coverslip, a
second microarray slide was used. This provides a repli-
cated measurement for each hybridization that can be used
for quality control and to reduce technical variability.
For each condition, we generated four sandwich experi-
ments. For each spot, median signal and background
intensities for both channels were obtained. The back-
ground-corrected ratio of the two channels was calculated
and log2 transformed. To balance the ﬂuorescence inten-
sities for the two dyes, as well as to allow for comparison of
expression levels across experiments, the raw data were
standardized. We used the printtip-lowess normalization
to correct for inherent bias on each chip (35). Expression
data and gene annotations were stored in Array Express
accession no. E-MEXP-1173 (http://www.ebi.ac.uk/array
express/), which complies with MIAME (minimal
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The R environment (http://www.r-project.org/) was used
for gene ﬁltering and normalization of the data.
Reverse transcription (RT) andquantitative PCR(QPCR)
Total RNA from HeLa cells was isolated using the
peqGOLD total RNA kit (PeqLab). Two micrograms of
RNA were applied to RT by incubation with 0.5mg
oligo(dT)17 primer and 100U M-MLV reverse transcrip-
tase (Invitrogen). cDNA was analysed by QPCR, which
was performed using SybrGreen (Bioline, Luckenwalde,
Germany) and the Mx3000P real-time detection system
(Stratagene, La Jolla, CA/USA). For RT–QPCR we
used the following primers: hGAPDH forward 50-
AGCCACATCGCTCAGACAC-30 and reverse
50-GCCCAATACGACCAAATCC-50,h C A R M 1f o r w a r d
50-CACACCGACTTCAAGGACAA-30 and reverse 50-AA
AAACGACAGGATCCCAGA-30,h P R M T 1f o r w a r d
50-GAGAATTTTGTAGCCACCTTGG-30 and reverse
50-CCTGGCCACAGGACACTT-30,h K R T 8f o r w a r d
50-AACGAATTTGTCCTCATCAAGAA-30 and reverse
50-GTTGATCTCGTCGGTCAGC-30, hCITED2 forward
50-TCACTTTCAAGTTGGCTGTCC-30 and reverse
50-CATTCCACACCCTATTATCATCTGT-30. All ampli-
ﬁcations were performed in triplicates using 0.5ml cDNA
per reaction. The triplicate mean values were calculated
accordingtothectquantiﬁcation method(36) usingthe
GAPDH gene transcription as reference for normalization.
Standard deviation was calculated from the triplicates.
Error bars are accordingly indicated. Gene transcription
was expressed as fold increase in mRNA level, whereas the
mRNA level in uninduced control (siNON-targeting) cells
was equated 1 and all other values were expressed relative
to this. The represented RT–QPCR assays were repro-
duced at least three times in independent experiments with
the same results. Representative data sets are shown.
ChIP
Cells were crosslinked in the presence of 1% formaldehyde
at 378C for 10min and harvested after twice washing
with cold PBS. ChIP was performed as previously
described (22). Immunoprecipitated and eluted DNA
was puriﬁed with QIAquick columns (Qiagen, Hilden,
Germany) and ampliﬁed by QPCR with the following
primers: the CITED2 promoter region (nt  1324 to
 1054, encompassing the STAT5 binding site) forward
50-GCCCAGACCTGTGTTAGGGGTTT-30 and reverse
50-TGAGTAAGGCTGCTCTTGCTGGA-30 and as con-
trol an intergenic promoter-free control region upstream
of the CITED2 gene (nt  6835 to  6493) forward
50-CTCAGAAGAGCCCAGTGTAGCA-30 and reverse
50-GGATGAGGTATGTTGGAAAGCAGA-30.
Ampliﬁcations were performed in triplicates and mean
values were normalized to the values of chromatin
enrichment by the control IgGs and expressed as fold
control IgG, which was equated 1.
Reporter geneassay
HeLa cells were plated in 24-well dishes. After 24 h, cells
were transiently transfected at a conﬂuency of 50% with
2mg of DNA per well (500ng reporter plasmid and CMV-
b-Gal, 300ng of various expression plasmids ﬁlled up with
mock plasmid DNA) using the Ca-Phosphat technique.
Twenty-four hours post transfection medium was
changed. Sixteen hours before harvesting, IL-4 stimula-
tion was performed. Finally, 48h post transfection cells
were washed with PBS and subsequently harvested in
passive lysis buﬀer (Promega, Madison, WI, USA).
Luciferase assays were performed by adding 350ml2m M
ATP solution and 150ml luciferin solution (0.2mM in
25mM glycylglycine pH 7.8) to 10ml lysate. RLU (relative
light units) were measured in a Berthold Lumat LB 9507
luminometer. To normalize for transfection eﬃciency
b-Gal assays were conducted by incubation of 50ml lysate
with o-nitrophenyl b-D-galactopyranoside solution (400mg
of ONPG in 60mM Na2HPO4/40mM NaH2PO4 pH 8,
10mM KCl, 1mM MgCl2,5 0 m Mb-mercaptoethanol)
at 378C and subsequent determination of OD420 in the
photometer. For normalization, the luciferase values
(in RLU) were calculated relative to b-Gal values. Each
transfection was performed in triplicates. Error bars show
the standard deviation of the triplicates in a representative
experiment. Experiments were repeated several times.
GST-pulldown experiments
GST, GST-CARM1 and GST-PRMT1 fusion proteins
were expressed in and puriﬁed from Escherichia coli BL21
according to standard procedures. Two micrograms of
each fusion protein immobilized on glutathione–agarose
beads were blocked with bovine serum albumine
(200mg/ml) for 1h at 48C. In parallel, HeLa whole-cell
extract was prepared after Ca-phosphat transfection of
STAT5b using IPH buﬀer (50mM Tris/HCl pH 8,
150mM NaCl, 0.5% NP-40, 1mM DTT) and precleared
with glutathione beads. Subsequently, the blocked GST-
fusion beads were incubated with 250mg of the precleared
cell extract for 2h at 48C. After intense washes of
the beads in IPH buﬀer bound proteins were resolved by
SDS–PAGE and analysed by anti-STAT5 Western Blot.
Immunoprecipitation analysis
Nuclear extracts were prepared from HeLa cell. Cells were
washed in cold PBS and subsequently lysed in BuﬀerA
(10mM HEPES–KOH, pH 7.9, 10mM KCl, 1.5mM
MgCl2, 0.04% NP-40, 2mM Na3VO4, 150mM NaF) for
5min. After centrifugation, the cytosolic components were
removed. The remaining nuclear pellet was resolved in
BuﬀerB (20mM HEPES–KOH, pH 7.9, 400mM KCl,
1.5mM MgCl2, 0.2mM EDTA, 0.5% NP-40, 2mM
Na3VO4, 150mM NaF) and incubated under rotation for
20min at 48C. Debris was removed by centrifugation and
the clear lysates were diluted 1:1 with Dilution Buﬀer
(20mM HEPES–KOH, pH 7.9, 0.5% NP-40). Five
hundred micrograms of nuclear extract were incubated
with 1–2mg of the indicated antibodies at 48C overnight
and subsequently incubated with protein A and G
sepharose (GE Health Care, Mu ¨ nchen, Germany). After
extensive washes in IPH buﬀer precipitates were analysed
by SDS–PAGE and Western Blot.
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Identification ofnovel target genesof CARM1 and
PRMT1 bycDNA microarrayanalysis
To identify novel transcriptional targets of CARM1 and/
or PRMT1, we established single and double knockdowns
using transient transfection of soluble double-stranded
siRNAs to deplete one or both enzymes in HeLa cells. We
employed two diﬀerent siRNA sequences against each
enzyme: siCARM1_1 or siCARM1_2 targeting CARM1
and siPRMT1_1 or siPRMT1_2 targeting PRMT1. Forty-
eight hours post transfection, the endogenous expression
of CARM1 and/or PRMT1 was eﬃciently suppressed on
RNA (Figure 1A) and protein level (Figure 1B) with the
aid of both alternative siRNAs in single as well as double
knockdown experiments compared to control siRNA
(siNON-targeting) transfection.
Subsequently we explored the gene expression proﬁles
of these single or double PRMT-depleted HeLa cells
relative to control (siNON-targeting transfected) cells
by hybridization of a human cDNA microarray, which
represents 11552 human cDNAs. Microarray analysis was
perfomed for both alternative siRNAs in duplicates and
additionally in ﬂip-colour experiments. As we obtained in
total eight independent data sets for each gene and
knockdown condition, mean log2 ratios (M-values) were
calculated from replicates and used to compare the
diﬀerent conditions. To select for diﬀerentially expressed
genes we used the signiﬁcance analysis of microarrays (37)
allowing a false-discovery rate (A-value) of  7% and a
fold change (M-value) of at least 2 or a log2 of  1o r  1,
as indicated in the MA-scatterplots of Figure 2. Therefore,
genes indicated by red-coloured spots were considered
deregulated or diﬀerentially expressed. The MA-plot
revealed no signiﬁcant changes in the overall expression
pattern for the CARM1 and PRMT1 single knockdown
versus control knockdown cells (Figure 2A and B).
Figure 2. Changes in the expression pattern of CARM1/PRMT1 single
and double knockdown cells analysed by MA-scatterplot of the entire
averaged microarray data set. The MA-scatterplot illustrates the
distribution of log expression ratios (M-values) comparing single or
double knockdown cells with siNON-targeting transfected (control)
cells and the normalized ﬂuorescence intensity values (A-values) for
each of the 11552 genes, which were spotted on the cDNA microarray.
The presented results reﬂect the average of eight independent
microarray hybridizations. Genes indicated by red-coloured spots
were considered signiﬁcantly deregulated, i.e. they displayed M-values
 1o r  1(  2-fold expression changes) and A-values  7%.
(A) Scatterplot for CARM1 single knockdown versus control HeLa
cells. (B) Scatterplot for PRMT1 single knockdown versus control
HeLa cells. (C) Scatterplot for CARM1/PRMT1 double knockdown
versus control HeLa cells.
Figure 1. Establishment of the CARM1/PRMT1 single and double
knockdown in HeLa cells. (A) HeLa cells were transfected with siNON-
targeting or two alternative siRNAs against CARM1 (siCARM1_1 or
siCARM1_2) and/or two alternative siRNAs against PRMT1
(siPRMT1_1 or siPRMT1_2) for 48h. Subsequently total RNA was
analysed by RT–QPCR for CARM1 (dark grey bars) and PRMT1
transcription (bright grey bars) respectively normalized for GAPDH.
(B) HeLa cells were treated with siRNAs as in (A). Forty-eight hours
post transfection cells were harvested in SDS-lysis buﬀer and 50mlo f
each sample were stained by Western Blot with the indicated antibodies.
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PRMT1on global transcription
The MA-plot of double knockdown cells versus con-
trol cells identiﬁed 63 genes, which were >2-fold
diﬀerentially expressed and were considered signiﬁcantly
deregulated (Figure 2C). Forty-six out of these deregu-
lated genes exhibited a similar expression change when the
two alternative siRNAs against CARM1 and PRMT1
were compared. Therefore the group of 46 genes, which
are listed in Figure 3A, represent bona ﬁde targets of both
enzymes. Among them, 23 genes were downregulated and
23 genes were upregulated in their expression. PRMT1
itself was the strongest deregulated gene (5.2-fold down-
regulated, Figure 3A) and served as an internal control,
whereas the CARM1 cDNA was not spotted on our array.
We then analysed in detail the mean expression changes of
the 20 strongest deregulated genes in double knockdown
cells in comparison to their expression in single knock-
down cells (Figure 3B). In agreement with the MA-plot
analysis, we found weak diﬀerential expression for these
genes in the single knockdown conditions (mostly below
log2 value of 0.5) and stronger diﬀerential expression in
the double knockdown conditions. A subset of the 46
deregulated targets was also validated by RT–QPCR from
independent knockdown experiments (Supplementary
Figure 1) conﬁrming that single knockdown of either
CARM1 or PRMT1 reduced the transcript levels of these
genes, but double depletion of both enzymes caused a
synergistically stronger eﬀect. These results suggest a
predominantly cooperative or redundant function of
CARM1 and PRMT1 in global gene expression.
Regulation of CITED2by STAT5, CARM1 andPRMT1
In the following, we raised the question whether the
diﬀerentially expressed genes of our microarray analysis
might be transcriptional targets of CARM1 and PRMT1.
Accordingly, we aimed to identify transcription factors,
which might be responsible for recruitment of the two
PRMTs to target gene promoters and might coregulate
a subset of the identiﬁed genes. Such promoter analysis
could point to novel signalling pathways that are coopera-
tively regulated by CARM1 and PRMT1. Therefore, we
searched for conserved cis-regulatory elements in the 46
target gene promoters by using the TRANSFAC database
on promoter segments conserved among human, mouse
and rat (38). This analysis suggested the existence of
potential binding sites of STAT5 and STAT6 (signal
transducer and activator of transcription 5 and 6) tran-
scription factors respectively in a subset of the down-
regulatedgenes,amongthemtheCITED2andKRT8gene.
No enrichment for transcription factor binding sites was
found among the upregulated genes (data not shown).
Given that the CITED2 gene expression was previously
shown to be inducible upon treatment with various
cytokines (39), we investigated whether the transcription
of CITED2 and also KRT8 depends on STAT5 and/or
STAT6. IL-4 is the canonical stimulus for STAT6 and has
been reported to induce STAT6-dependent transcription
in HeLa cells (40,41). Additionally, it was suggested that
IL-4 stimulates STAT5 signalling in T-lymphocytes (42).
Figure 3. Analysis of the by CARM1/PRMT1 double knockdown
signiﬁcantly deregulated genes. (A) List of the 46 deregulated genes
from the microarray analysis. Fold change of expression, direction of
deregulation, accession number and gene symbol are indicated for each
gene. (B) Comparison of the expression changes (in log2 or M-values)
of the 20 strongest deregulated genes and the KRT8 gene in the double
knockdown cells with their expression in the single knockdown cells.
Black bars indicated the average expression change in CARM1/
PRMT1 double knockdown cells (versus control cells). Grey bars
indicated the average expression change in CARM1 single knockdown
cells (versus control cells). White bars indicated the average expression
change in PRMT1 single knockdown cells (versus control cells).
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indicated time course and analysed phosphorylation of
STAT5 and STAT6 by Western Blot (Figure 4A). Upon
IL-4 stimulus tyrosine phosphorylation of both transcrip-
tion factors was detectable indicating that STAT5 and
STAT6 signalling is activated under these conditions in
HeLa. RT–QPCR of untreated and IL-4-treated HeLa
cells revealed that the transcript levels of CITED2 and
KRT8 were enhanced upon IL-4 exposure (Figure 4B).
These results identiﬁed CITED2 and KRT8 as IL-4-
inducible genes in HeLa cells.
Next, we analysed whether the IL-4-mediated gene
activation of CITED2 and KRT8 depends on the two
PRMTs, STAT5 and STAT6, respectively. Thus, we
transfected HeLa cells with NON-targeting siRNA,
siCARM1/siPRMT1, siRNA against STAT5 or STAT6
and 24h post transfection IL-4 treatment was performed.
The eﬀective knockdown was conﬁrmed by Western Blot
for STAT5 and STAT6 (Figure 4C) and by RT–QPCR
for CARM1 and PRMT1 transcript levels (Figure 4D).
In agreement with our microarray analysis, RT–QPCR
revealed that the basal gene activity of KRT8 and
CITED2 was reduced upon CARM1/PRMT1 knockdown
(Figures 4D and 3B), which suggests that both genes are
already activated under normal growth conditions
(i.e. in the presence of FCS). In case of KRT8, the
IL-4-induced expression was not inﬂuenced upon knock-
down of CARM1/PRMT1 or STAT5, but diminished
upon knockdown of STAT6 (Figure 4D) indicating that
its IL-4-stimulated transcription might be regulated by
STAT6 and not by STAT5 or the two PRMTs. In case
of CITED2, the IL-4-induced expression was abolished
upon knockdown of CARM1/PRMT1 and both STATs
(Figure 4D). Given that STAT6 knockdown reduced the
expression of CARM1 and PRMT1, STAT6 might exert
its eﬀect on CITED2 transcription indirectly by regulating
the coactivator levels. STAT5 knockdown however did
not inﬂuence the expression of the PRMTs (Figure 4D)
suggesting that STAT5 might activate CITED2 expression
directly on the promoter level. These results indicate that
transcription of CITED2 in IL-4 signalling is regulated by
STAT5, CARM1 and PRMT1.
CITED2is adirect targetgene ofSTAT5, CARM1
andPRMT1
To elucidate the potential coactivator function of CARM1
and PRMT1 for the STAT5 transcription factor at the
CITED2 gene, we investigated whether CITED2 is a
direct target gene of CARM1, PRMT1 and STAT5.
Therefore, we analysed the recruitment of both PRMTs
and STAT5 to the CITED2 gene promoter by ChIP. As
we originally identiﬁed CITED2 as a PRMT1/CARM1
target in a microarray analysis with normal FCS growth
conditions but without IL-4 stimulation, we asked
whether FCS and IL-4 costimulation would cooperatively
enhance CITED2 gene activation. Indeed, we found that
transcript levels of CITED2 were stronger increased by
costimulation of starved HeLa cells with FCS and IL-4
than by individual stimulation with FCS or IL-4
(Figure 5A). Therefore, we used for the ChIP analysis
FCS/IL-4 costimulated cells versus unstimulated cells. We
detected binding of STAT5 to a CITED2 gene promoter
fragment encompassing the putative STAT5-binding
Figure 4. A subset of downregulated microarray targets is inducible by IL-4 treatment depending on the presence of STAT5, CARM1 and PRMT1.
(A) HeLa cells were treated without (0h) or with IL-4 for the indicated times (1h and 4h). Subsequently, cells were harvested in SDS-lysis buﬀer and
50ml of each sample were analysed by Western Blot with the indicated antibodies. (B) HeLa cells were treated without ( ) or with (+) IL-4 for 16h.
Subsequently, cells were harvested and total RNA was analysed by RT–QPCR for transcript levels of CITED2 and KRT8 normalized for GAPDH.
(C) HeLa cells were transfected with siNON-targeting, siCARM1/siPRMT1, siSTAT5 or siSTAT6 for 24h and harvested in SDS-lysis buﬀer. Fifty
microlitres of each sample were analysed by Western Blot with the indicated antibodies. (D) HeLa cells were transfected with siNON-targeting,
siCARM1/siPRMT1, siSTAT5 or siSTAT6 for 24h. Subsequently, cells were treated without ( , black bars) or with (+, grey bars) IL-4 for 24h.
Total RNA was analysed by RT–QPCR for transcript levels of CARM1, PRMT1 and CITED2 normalized for GAPDH.
Nucleic Acids Research, 2008, Vol. 36, No. 10 3207Figure 5. CARM1 and PRMT1 are recruited in an IL-4-dependent manner to the endogenous CITED2 gene promoter and cooperatively coactivate
STAT5 in an IL-4-dependent manner. (A) Starved HeLa cells (0.1% FCS) were treated without ( ) or with (+) IL-4 and/or 10% FCS for 16h.
Subsequently, cells were harvested and total RNA was analysed by RT–QPCR for transcript levels of CITED2 normalized for GAPDH.
(B), Scheme of the CITED2 gene illustrating the location of the putative STAT5-binding site within the promoter. (C and D) Starved HeLa
cells (0.1% FCS) were treated without ( , black bars) or with 10% FCS/IL-4 (+, grey bars) for 16h. Subsequently, cells were harvested and
subjected to ChIP analysis using antibodies against STAT5 (corresponding control antibody: IgG), PRMT1 (corresponding control antibody:
preimmune-PRMT1) and CARM1 (corresponding control antibody: preimmune-CARM1). Immunoprecipitated DNA was analysed in triplicates by
QPCR with primers for the CITED2 gene promoter encompassing the STAT5-binding site (in C) and an intergenic control region 6-kb upstream of
the CITED gene (in D). Mean values were expressed as fold control IgG, which was equated 1. (E) Starved HeLa cells (0.1% FCS) were treated
without ( , black bars) or with 10% FCS/IL-4 for 2, 8 and 16h. Subsequently, cells were harvested and subjected to ChIP analysis using control
antibodies (IgG), antibodies against STAT5, H4 R3me2, H3 R17me2, PRMT1 and CARM1. Immunoprecipitated DNA was analysed in triplicates
by QPCR with primers for the CITED2 gene promoter as in C. (F) HeLa cells were transiently transfected with a (STAT5-RE)6-luciferase (luc)
reporter gene constructs and a CMV-b-galactosidase reporter (the latter for normalization) in the absence or presence of expression constructs for
STAT5b, CARM1 and PRMT1. Twenty-four hours after transfection medium was changed and cells were treated without ( , black bars) or for 16h
with IL-4 (+, grey bars). Subsequently, cells were harvested and assayed for luciferase activity. Values given are the mean of triplicate measurements
and expressed relative to the b-galactosidase activity. Equal protein expression was conﬁrmed by Western Blot (data not shown).
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was not enhanced upon FCS/IL-4 stimulation for 16h
(Figure 5C). In contrast, CARM1 and PRMT1 were not
bound at the CITED2 gene promoter in unstimulated
cells, but became recruited upon 16h of FCS/IL-4
treatment coinciding with transcriptional activation of
the gene (Figure 5A and C). Neither of the two PRMTs
nor STAT5 were detected on an intergenic control
fragment 6-kb uptream of CITED2 gene (Figure 5D).
To investigate whether STAT5 is indeed constitutively
bound to the CITED2 gene promoter, we performed ChIP
analysis of uninduced, 2, 8 and 16h FCS/IL-4-stimulated
HeLa cells. As shown in Figure 5E, recruitment of STAT5
was already weakly detectable in the uninduced state,
peaked after 8h of induction and was barely visible after
16h in agreement with Figure 5C. These ﬁndings suggest
that promoter association of STAT5 is an early and
transient event subsequent to its activation. Similar to
STAT5, CARM1 recruitment to the CITED2 promoter
was stimulus dependent and reached its maximum after
8h of FCS/IL-4 treatment, whereas PRMT1 remained
associated up to the 16h time point (Figure 5E).
To address the question whether the histone arginine
methyltransferase activity of the two PRMTs is involved
in their coactivation function at the CITED2 gene, we
performed ChIP analysis with antibodies recognizing
the modiﬁcation site of PRMT1 (H4 R3me2) and
CARM1 (H3 R17me2) in histones (43,44). Coinciding
with the recruitment of PRMT1 and CARM1, we found
increased H4 R3 dimethylation and H3 R17 dimethylation
at the 8h induction time point (Figure 5E). These
data indicate that CITED2 is a direct target gene of
IL-4-induced coactivation by CARM1 and PRMT1
and that the histone arginine methyltransferase
activity of the two PRMTs might be required for gene
activation.
Coactivation of STAT5-mediated transcription by
CARM1 and PRMT1
To conﬁrm the coactivator function of CARM1 and
PRMT1 for the STAT5 transcription factor in an
independent and more general experimental setting, we
employed reporter gene assays using a reporter constructs
with multimerized STAT5-response elements of the
b-casein promoter cloned upstream of the luciferase gene
(STAT5-RE)6-luc (45,46). HeLa cells were transfected
with the (STAT5-RE)6-luc reporter in the absence and
presence of STAT5b expression plasmid and IL-4
stimulus, respectively. The basal activity of the luciferase
reporter was stimulated by 10-fold depending on the over-
expression of STAT5b and IL-4 stimulus (Figure 5E).
Overexpression of either CARM1 or PRMT1 resulted in a
slight increase of the STAT5b/IL-4-dependent luciferase
activity, whereas cotransfection of both PRMTs clearly
enhanced the STAT5b/IL-4-stimulated reporter activity
>2-fold (Figure 5E). These results suggest that CARM1
and PRMT1 coactivate STAT5-regulated transcription in
a cytokine-dependent and cooperative manner.
Cytokine-enhanced interaction between STAT5 and
thetwo PRMTs
Given that STAT5, CARM1 and PRMT1 appear to
collaborate in transcriptional activation and overlap in
their promoter recruitment to a common target gene,
we investigated whether CARM1 and PRMT1 are able
to interact with STAT5b and whether this interaction is
altered by a transcriptional stimulus like IL-4. Therefore,
we ﬁrst performed GST pulldown experiments with the
aid of GST (as control), GST-PRMT1 or GST-CARM1
immobilized on agarose beads (Figure 6A, bottom panel)
in the presence of unstimulated and IL-4-stimulated HeLa
cell extracts overexpressing STAT5b. Subsequently, the
pulldowns were analysed by anti-STAT5 Western
Blot. As shown in Figure 6A (top panel), CARM1 and
PRMT1 weakly interacted with exogenous STAT5b
before stimulation and revealed enhanced interaction
with STAT5b in IL-4-stimulated cell extracts. Similar
results were gained in a second experimental approach
by coimmunoprecipitation. Endogenous PRMT1 and
CARM1 respectively were immunoprecipitated from
unstimulated or IL-4-stimulated HeLa nuclear extracts.
Subsequently, the precipitates were probed for the
presence of endogenous STAT5 protein by Western Blot
analysis. As shown in Figure 6B, both PRMTs interacted
with STAT5 in vivo. PRMT1 precipitates contained
STAT5 only subsequent to IL-4 stimulation, whereas
CARM1–STAT5 interaction was already weakly detect-
able in unstimulated extacts and was enhanced upon IL-4
stimulation. These results indicate that CARM1 and
PRMT1 interact stimulus dependent with STAT5 corro-
borating the direct role of these three proteins in the
transcriptional control of the CITED2 gene in response to
IL-4 stimulation.
DISCUSSION
Using an unbiased microarray approach, we identiﬁed
novel target genes directly or indirectly regulated by
CARM1 and/or PRMT1, which have previously been
linked to transcriptional control. We could demonstrate
that single knockdown of neither CARM1 nor PRMT1
signiﬁcantly changed the global expression pattern in
HeLa cells, whereas double knockdown of both enzymes
resulted in >2-fold deregulation of 46 genes. One explana-
tion for this ﬁnding is that deregulated gene expression
upon codepletion of both PRMTs demonstrates additive
eﬀects of the single knockdowns. Indeed, we found
evidence that CARM1 and PRMT1 cooperatively regulate
the CITED2 gene. However, we cannot exclude that
some targets might be redundantly regulated by the two
PRMTs. For example, neither CARM1 nor PRMT1 single
knockdown aﬀected RRAD expression (Supplementary
Figure 1), whereas other targets are at least slightly
deregulated under single knockdown conditions. Since
siRNA-mediated knockdown was eﬃcient (Figure 1)
but certainly incomplete, residual PRMT-activity might
complicatethediscrimination ofcooperatively fromredun-
dantly regulated target genes. Additionally, 48h of siRNA
treatment, which we employed in the microarray analysis
Nucleic Acids Research, 2008, Vol. 36, No. 10 3209to circumvent secondary eﬀects, might not be suﬃcient
to allow complete depletion of the corresponding methyla-
tion marks and to reveal a clear synergism of the two
enzymes in gene expression.
In general, our data suggest a more widespread coope-
ration and overlap of target genes between CARM1 and
PRMT1 than so far reported in the literature. Most studies
investigated the individual coregulator function of either
CARM1 or PRMT1 on distinct transcription factors and
signalling pathways besides two examples in the literature,
which describe synergism between the two enzymes in
p53- and NR-mediated transcription (21,24). Given that
the two PRMTs possess non-overlapping substrate speci-
ﬁcity and their recruitment to p53 and NR target gene
promoters is temporally separated (11,24,43,47), it was
suggested that they fullﬁl non-redundant functions in
p53- and NR-signalling. PRMT1 is targeted very early
during the initial phase of transcriptional activation
to these target gene promoters, whereas CARM1 subse-
quently appears at the promoters triggering late
coactivation events and also disassemby of coactivator
complexes (24,26,27). As our aim was to identify novel
target genes and pathways regulated by the two arginine
methyltransferases, we did not speciﬁcally stimulate
steroid-hormone signalling in our experiments. Further-
more p53 signalling is inactive in HeLa cells because of
E6 expression from human papillomavirus (48). Therefore,
we did not expect to identify any cooperatively regulated
target genes of these two known pathways in our screen.
Interestingly, among the 46 deregulated target genes of
CARM1 and PRMT1, genes were downregulated as well
as upregulated upon depletion of the enzymes indicating
that the two enzymes cooperate in activation as well
as repression of gene expression. Arginine methylation
of histones by the two enzymes, i.e. R17 in histone H3
by CARM1 and R3 in histone H4 by PRMT1, have up
to now exclusively been linked to transcriptional activa-
tion (11,43), whereas arginine methylation of non-histone
chromatin proteins was also found to be involved in
transcriptional repression. For example, arginine methyl-
ation of the histone acetyltransferase CBP/p300 by
CARM1 has been reported to occur at various sites.
Figure 6. CARM1 and PRMT1 interaction with STAT5 is enhanced by IL-4. (A) GST alone (control), GST-CARM1 and GST-PRMT1 were
expressed in E. coli and puriﬁed. Equal amounts of these GST-fusions, as indicated in the Coomassie-stained SDS-gel (bottom panel, full-length
protein bands marked with asterisks), coupled to glutathione beads were used in pulldown experiments in the presence of HeLa whole-cell extract
overexpressing STAT5b and treated without or with IL-4 for 16h. Interactions between the proteins were detected by anti-STAT5 Western Blot (top
panel). One percent input of HeLa whole-cell extract is shown. (B) HeLa cells were left unstimulated or stimulated with IL-4 for 1 or 16h.
Subsequently, nuclear extracts were prepared and subjected to immunoprecipitation with antibodies against PRMT1, CARM1 and as control IgG.
Immunoprecipitates were resolved by SDS–PAGE and analysed by Western Blot analysis with the indicated antibodies to conﬁrm the
immunoprecipitation of PRMT1 and CARM1 (as control) and to investigate STAT5 coimmunoprecipitation. Ten percent input (50mg) of HeLa cell
extract is shown.
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CBP/p300 by CARM1 was shown to inhibit its interaction
with the CREB transcription factor and hence abolishes
cAMP-activated gene expression (25). Other reports ﬁnd
methylation of CBP/p300 within its C-terminal interac-
tion surface for the p160 proteins, which abolishes interac-
tion between CBP/p300 and GRIP1 (49). In contrast,
methylation of the central part of CBP/p300 by CARM1
enhances the coactivation function of the HAT in
NR-mediated transcription (50). The p160 family mem-
bers SRC-1 and SRC-3 are regulated as well by CARM1-
dependent methylation, as they become methylated in
their glutamine-rich region. This methylation event
associates with decreased protein stability of p160,
disassembly of the p160-CBP/p300 coactivator complex
and accordingly reduction of the transcriptional activity
(26,27). Modiﬁcation of non-histone chromatin proteins
by PRMT1 is also linked to transcriptional activation and
repression. The NR transcription factor HNF-4 becomes
methylated in its DNA-binding domain by PRMT1,
which enhances DNA-binding aﬃnity of HNF-4 and
subsequent coactivation (51). In contrast, the elongation
factor Spt5 is methylated by PRMT1, which regulates its
interaction with RNA polymerase II and causes transcrip-
tional pausing (52). Taking the literature into account,
which describes mechanisms for transcriptional regulation
either by CARM1 or by PRMT1, it appears plausible that
the enzymes might not only cooperate in activation but
also in repression of transcription.
PRMTs possess many other cellular interaction part-
ners and substrates besides histones and non-histone
chromatin proteins, for example the RNA-binding protein
HuD, whose methylation by CARM1 inﬂuences p21
mRNA stability (53). Therefore, some of our diﬀerentially
expressed microarray targets might be regulated indirectly
and/or posttranscriptionally by the two PRMTs, e.g. on
the level of RNA stability, protein turnover, cellular
localization or other mechanisms. Further work has to be
done to dissect transcriptional from non-transcriptional
targets identiﬁed in our microarray approach.
As transcriptional cooperation of CARM1 and PRMT1
is mediated by sequence-speciﬁc transcription factors,
we searched for common transcription factor binding site
in the 46 deregulated targets. Promoter analysis suggested
that a subset of downregulated genes might be regulated
by STAT5 and/or STAT6. STATs are downstream
targets of various cytokines and lipophilic hormones,
like erythropoetin and prolactin (40,54). Cytokine stimu-
lation and subsequent phosphorylation of STATs by
cytokine receptor-associated kinases results in nuclear
translocation of STATs and activation of a variety of
genes involved in the control of proliferation, apoptosis
and diﬀerentiation. Although IL-4 is the canonical
stimulus for STAT6-activated transcription (40), it was
previously reported to activate also STAT5 signalling (42).
IL-4 treatment induces the expression of two microarray
targets, namely CITED2 and KRT8. CARM1/PRMT1
codepletion and STAT5 depletion, respectively abolished
IL-4 induced expression of CITED2, whereas KRT8
expression was unaﬀected under these conditions. This
observation identiﬁed CITED2 as a CARM1/PRMT1 and
STAT5 target in IL-4 signalling. In agreement with this
observation, the CITED2 gene, which encodes a nuclear
protein interacting with CBP/p300 and interfering with
hypoxia-driven transcription, was previously shown to be
transcriptionally activated upon cytokine treatment
(39,55) and was identiﬁed as a STAT5 target gene (56).
As knockdown of STAT6 inhibited the expression of
CARM1 and PRMT1, we suggest that STAT6 regulates
CITED2 gene expression indirectly. In agreement with
the ﬁnding that IL-4 induced KRT8 expression depends
neither on CARM1, PRMT1 nor STAT5, but on STAT6,
we could not detect coactivator function of both PRMTs
using a STAT6-dependent reporter gene (data not shown).
Instead, we detected cooperative coactivation of IL-4
induced STAT5-mediated transcription by CARM1
and PRMT1 in reporter gene assays. As we found that
PRMT1/CARM1 did not coactivate the transcript levels
of other well-known STAT5 target genes, like Cis and
bCasein (data not shown), we conclude that the two
PRMTs are no general coactivators of STAT5, but act on
a subset of STAT5 targets, e.g. CITED2.
ChIP analysis identiﬁed CITED2 as a direct target gene
of CARM1 and PRMT1, as we could detect the
recruitment of both coregulators to the gene promoter
subsequent to FCS/IL-4 stimulation. Similarly, promoter
association of STAT5 was increased by the FCS/IL-4
stimulus and presented an early and transient event.
Furthermore, in GST-pulldown and endogenous
coimmunoprecipitation experiments STAT5 interacted
with both PRMTs in an IL-4-dependent manner. Alto-
gether, these data suggest that CARM1 and PRMT1
cooperatively enhance STAT5-dependent transcriptional
activation of CITED2 on the promoter level in IL-4
signalling and that the IL-4 stimulus enforces the inter-
action of the two coactivators with STAT5 and their
promoter recruitment.
Previous reports proposed that arginine methylation
plays an important role in cytokine signalling either on the
level of the cytokine receptor or on the level of the STAT
transcription factors (57–59). Although it was suggested
that STAT1 and STAT6 are themselves substrates of
arginine methylation and that this modiﬁcation event
enhances their coactivation function (58,59), arginine
methylation of STAT transcription factors is still under
debate (60,61). Based on our ChIP data, in which we
detected increased H4 R3 and H3 R17 dimethylation at the
CITED2 gene promoter upon FCS/IL-4 stimulation coin-
ciding with the promoter recruitment of the two PRMTs, it
seems likely that CARM1 and PRMT1 regulate STAT5-
dependent transcription due to histone methylation.
Whether arginine methylation of other promoter-bound
proteins by PRMT1 and/or CARM1 is also required in the
coactivation process of the CITED2 gene should be
addressed in the future. Interestingly, STAT5 uses a
similar set of coactivator proteins as p53 and NR trans-
cription factors, for example p160 proteins, p300/CBP
(62,63) and PRMTs, as we show here. This suggests that a
common coactivator complex consisting of a p160 family
member, histone acetyltransferase and arginine methyl-
transferase activities might cooperatively contribute to
gene activation by various transcription factors.
Nucleic Acids Research, 2008, Vol. 36, No. 10 3211In summary, our microarray data present a ﬁrst
unbiased study, which globally searches for individual
and overlapping target genes of CARM1 and PRMT1 and
unravels a more general cooperation in transcriptional
regulation of the two enzymes than so far expected.
Further, we identiﬁed IL-4-stimulated STAT5-dependent
CITED2 expression as a novel pathway coregulated by the
two PRMTs.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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